George C. Avgerinos
Net Worth
Last updated:
What is George C. Avgerinos net worth?
The estimated net worth of Dr. George C. Avgerinos is at least $10,118,009 as of 11 Dec 2018. He owns shares worth $2,500,666 as insider, has earned $660,343 from insider trading and has received compensation worth at least $6,957,000 in Fortress Biotech, Inc. and Fortress Biotech, Inc..
What is the salary of George C. Avgerinos?
Dr. George C. Avgerinos salary is $386,500 per year as Senior Vice President of Biologics Operations in Fortress Biotech, Inc.. He also receives $386,500 as Senior Vice President of Biologics Operations in Fortress Biotech, Inc..
How old is George C. Avgerinos?
Dr. George C. Avgerinos is 71 years old, born in 1954.
What stocks does George C. Avgerinos currently own?
As insider, Dr. George C. Avgerinos owns shares in 2 companies:
| Company | Title | Shares | Price per share | Total value |
|---|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | Senior Vice President of Biologics Operations | 255,170 | $2.23 | $569,029 |
| Fortress Biotech, Inc. (FBIOP) | Senior Vice President of Biologics Operations | 255,170 | $7.57 | $1,931,637 |
What does Fortress Biotech, Inc. do?
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
What does Fortress Biotech, Inc. do?
Fortress Biotech, Inc., a biopharmaceutical company, develops and commercializes pharmaceutical and biotechnology products. The company markets dermatology products, such as Ximino capsules to treat only inflammatory lesions of non-nodular moderate to severe acne vulgaris; Targadox for severe acne; Exelderm cream for ringworm and jock itch symptoms; Ceracade for dry skin conditions; Luxamend for dressing and managing wounds; and Accutane capsules for severe recalcitrant nodular acne. It also develops late stage product candidates, such as intravenous Tramadol for the treatment of post-operative acute pain; CUTX-101, an injection for the treatment of Menkes disease; MB-107 and MB-207 for the treatment of X-linked severe combined immunodeficiency; Cosibelimab for metastatic cancers; CK-101 for the treatment of patients with EGFR mutation-positive NSCLC; CAEL-101 for the treatment of amyloid light chain amyloidosis; Triplex vaccine for cytomegalovirus; and CEVA101 for the treatment of severe traumatic brain injury in adults and children. The company's early stage product candidates include MB-102 for blastic plasmacytoid dendritic cell neoplasm; MB-101 for glioblastoma; MB-104 for multiple myeloma and light chain amyloidosis; MB-106 for B-cell non-hodgkin lymphoma; MB-103 for GBM & metastatic breast cancer to brain; MB-108; MB-105 for prostate and pancreatic cancers; and BAER-101. Its preclinical product candidates comprise AAV-ATP7A gene therapy; AVTS-001 gene therapy; CK-103 BET inhibitor; CEVA-D and CEVA-102; CK-302, an anti-GITR; CK-303, an anti-CAIX; ConVax; and ONCOlogues, and oligonucleotide platform. It has collaboration arrangements with universities, research institutes, and pharmaceutical companies. The company was formerly known as Coronado Biosciences, Inc. and changed its name to Fortress Biotech, Inc. in April 2015. Fortress Biotech, Inc. was incorporated in 2006 and is based in Bay Harbor Island, New York.
George C. Avgerinos insider trading
Fortress Biotech, Inc.
Dr. George C. Avgerinos has made 6 insider trades between 2016-2018, according to the Form 4 filled with the SEC. Most recently he sold 97,325 units of FBIO stock worth $102,191 on 11 Dec 2018.
The largest trade he's ever made was exercising 97,325 units of FBIO stock on 11 Dec 2018. As of 11 Dec 2018 he still owns at least 255,170 units of FBIO stock.
Fortress Biotech, Inc.
Dr. George C. Avgerinos has made 6 insider trades between 2016-2018, according to the Form 4 filled with the SEC. Most recently he sold 97,325 units of FBIOP stock worth $102,191 on 11 Dec 2018.
The largest trade he's ever made was exercising 97,325 units of FBIOP stock on 11 Dec 2018. As of 11 Dec 2018 he still owns at least 255,170 units of FBIOP stock.
Fortress Biotech key executives
Fortress Biotech, Inc. executives and other stock owners filed with the SEC:
- Dr. George C. Avgerinos (71) Senior Vice President of Biologics Operations
- Dr. Lindsay Allan Rosenwald (70) Executive Chairman, Pres & Chief Executive Officer
- Mr. Michael S. Weiss Esq. (59) Vice Chairman & Executive Vice Chairman of Strategic Devel.
- Ms. Robyn M. Hunter (63) Chief Financial Officer, Treasurer & Corporation Sec.